Embecta (EMBC) Cash from Financing Activities (2020 - 2026)
Embecta's (EMBC) quarterly Cash from Financing Activities came in at -$41.5 million in Q1 2026, down 11.26% year-on-year from -$46.8 million in Q1 2025, and up 19.57% quarter-over-quarter from -$51.6 million in Q4 2025.
Embecta (EMBC) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Embecta has disclosed Cash from Financing Activities across 7 years of filings, most recently posting -$41.5 million for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$41.5 million, down 11.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$237.3 million (down 81.7% YoY), and the FY2025 annual result was -$226.7 million, down 208.86% from the prior year.
- Cash from Financing Activities came in at -$41.5 million for Q1 2026 at Embecta, up from -$51.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $90.3 million in Q1 2022 to a low of -$81.6 million in Q3 2025.
- The 5-year median for Cash from Financing Activities is -$13.5 million (2023), against an average of -$20.9 million.
- Across the five-year window, Cash from Financing Activities soared 179.63% in 2022 and plunged 469.7% in 2023, its largest moves.
- Embecta's Cash from Financing Activities stood at -$6.1 million in 2022, then plunged by 121.31% to -$13.5 million in 2023, then slumped by 234.81% to -$45.2 million in 2024, then dropped by 14.16% to -$51.6 million in 2025, then climbed by 19.57% to -$41.5 million in 2026.
- The last three Cash from Financing Activities figures came in at -$41.5 million (Q1 2026), -$51.6 million (Q4 2025), and -$81.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -1.35 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -414.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -13.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -255.24 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -308.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -50.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -48.13 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -11.00 Mn |
| 10 | Embecta | 183.23 Mn | -10.17 Mn | 127.80 Mn | -41.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.50 Mn |
| Mar 31, 2026 | -41.50 Mn |
| Dec 31, 2025 | -51.60 Mn |
| Dec 31, 2025 | -51.60 Mn |
| Sep 30, 2025 | -81.60 Mn |
| Sep 30, 2025 | -81.60 Mn |
| Jun 30, 2025 | -62.60 Mn |
| Jun 30, 2025 | -62.60 Mn |
| Mar 31, 2025 | -37.30 Mn |
| Mar 31, 2025 | -37.30 Mn |
| Dec 31, 2024 | -45.20 Mn |
| Dec 31, 2024 | -45.20 Mn |
| Sep 30, 2024 | -36.60 Mn |
| Sep 30, 2024 | -36.60 Mn |
| Jun 30, 2024 | -11.50 Mn |
| Jun 30, 2024 | -11.50 Mn |
| Mar 31, 2024 | -11.80 Mn |
| Mar 31, 2024 | -11.80 Mn |
| Dec 31, 2023 | -13.50 Mn |
| Dec 31, 2023 | -13.50 Mn |